Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-label Study of Duvelisib in Relapsed or Refractory Peripheral T-cell Lymphoma
jRCT2080225029Phase 2Completed
- Sponsor
- Secura Bio
- Start
- Jan 2020
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of duvelisib in peripheral T-cell lymphoma (PTCL), sponsored by Secura Bio. Started Jan 2020; status: completed.
02
Drugs
duvelisib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on jRCT2080225029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225029.